Unlike generics, which are the exact chemical copies of a brand-name drug, biosimilars have large and often complex proteins that are made in living cells, and tiny differences can play havoc with the product. It may take years…
When IBM raised its buyback authorization by $10 billion on Oct. 26, it was the 259th company to announce repurchase plans in October alone. Citi Investment Research says a long-term trend of rising buybacks has only just begun…
Drug-makers Amgen and Johnson & Johnson are voluntarily recalling two brands of an injectable anemia medication because of the possibility that vials of it may also contain tiny glass flakes. The drug, Epoetin alfa, is marketed…